The short answer
What benfotiamine is.
Benfotiamine is a fat-soluble form of vitamin B1 (thiamine). That small chemical change allows the body to absorb it more easily than the standard, water-soluble version of B1. Researchers around the world have studied it for over six decades, and the body of research continues to grow — particularly around nerve function, cognition, and metabolic health.
The difference that matters
Absorption.
To understand why benfotiamine is interesting, it helps to understand a quiet problem with regular vitamin B1.
Standard B1 is water-soluble. To absorb it, the body has to actively pull it through the wall of the intestines using specialized transporter molecules. The system works — but it isn’t always efficient. A few common things can slow it down:
- Age. Absorption tends to decline as the body gets older.
- Heavy alcohol use. Alcohol interferes with how the intestines take up B1.
- Certain medications. Metformin, one of the most widely prescribed drugs in the world, has been shown to reduce B1 absorption.
The result is that a lot of people get less vitamin B1 than they assume they’re getting from food or a standard multivitamin.
Benfotiamine works around that bottleneck. Because it’s fat-soluble, it passes through the intestinal wall on its own — no transporters required. The body absorbs it more reliably, and more of it reaches the bloodstream.
Why B1 matters
The systems that depend on it.
Vitamin B1 is one of the body’s foundational nutrients. Two of its biggest jobs:
- Energy.B1 helps cells convert food into usable energy. Every cell needs it — but nerve cells and brain cells are especially dependent on it, because they’re metabolically demanding.
- Nerve function. B1 supports the chemistry that allows nerves to fire and communicate properly.
When B1 is low, the systems that lean on it the hardest tend to feel it first — which is part of why researchers have looked at benfotiamine in connection with nerve and brain health.
What the research has explored
Where the literature has looked.
Researchers have studied benfotiamine in connection with a range of conditions and symptoms. This is not a list of things benfotiamine treats — it’s a map of where the scientific literature has looked.
- Peripheral neuropathy — burning, tingling, numbness, and pain, often in the feet and legs.
- Diabetic polyneuropathy — nerve damage associated with diabetes and prediabetes.
- Alcohol-related neuropathy — nerve dysfunction associated with chronic alcohol use.
- Alzheimer’s disease and cognitive decline — studied for its role in brain energy metabolism.
- Parkinson’s disease — examined as part of a broader look at thiamine metabolism in neurological disease.
- ALS (amyotrophic lateral sclerosis) — case-report-level research on thiamine pathways.
- Long COVID brain fog — emerging research on lingering cognitive symptoms after COVID-19.
- Restless legs syndrome (RLS) — explored in case reports as connected to B1 status.
A brief history
Sixty years in the making.
Benfotiamine isn’t new. It has been used and studied worldwide for more than 60 years, primarily in Europe and Asia, where it has long been part of the conversation around nerve health.
It arrived in American medicine more recently — about 18 years ago — when Dr. Richard H. Mann introduced it to the US medical community. Since then, the research base in English-language journals has expanded substantially, and benfotiamine has moved from a little-known European nutrient to a subject of active clinical interest in the United States.
Safety
Well-tolerated, decades on.
In the published literature, benfotiamine has consistently been described as safe and well-tolerated, with no significant adverse effects reported in the studies cited across this site. It does not require a prescription. As with any supplement, anyone considering it should speak with a qualified healthcare provider — especially if they take other medications or manage an ongoing health condition.
Meet the researcher
References
- Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. “Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study.” Exp Clin Endocrinol Diabetes. 2008; 116(10):600-5.
- Haupt E, Ledermann H, Köpcke W. “Benfotiamine in the treatment of diabetic polyneuropathy—a three-week randomized, controlled pilot study (BEDIP Study).” Int J Clin Pharmacol Ther. 2005; 43(2):71-7.
- Woelk H, Lehrl S, Bitsch R, Köpcke W. “Benfotiamine in the treatment of alcoholic polyneuropathy: an 8-week randomized controlled study (BAP study).” Alcohol Alcohol. 1998; 33(6):631-8.
- Loew D. “Pharmacokinetics of thiamine derivatives, especially benfotiamine.” Int J Clin Pharmacol Ther. 1996; 34(2):47-50.
- Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M. “Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy.” Nat Med. 2003; 9(3):294-9.
- Pan X, Gong N, Zhao J, Yu Z, Gu F, Chen J, Sun X, Zhao L, Yu M, Xu Z, Dong W, Qin Y, Fei G, Zhong C, Xu TL. “Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice.” Brain. 2010; 133(Pt 5):1342-51.